Month: January 2024

William Moroney is promoted to President International and joins the Executive Committee Philip Barnett President Americas also joins the Executive Committee GENEVA, Jan. 15, 2024 (GLOBE NEWSWIRE) — Temenos (SIX: TEMN) today announced that William Moroney has been promoted to President International and joins the Executive Committee, with immediate effect. Philip Barnett, President Americas and member of the Management Board is also promoted to the Executive Committee. They both report to Temenos CEO Andreas Andreades. A key executive and member of the company’s Management Board, William Moroney is expanding his remit and will be responsible for Temenos’ international business across Europe, the Middle East & Africa, and Asia Pacific which represents 57% of the company’s total revenues. He will also have responsibility for...

Nasdaq CopenhagenLondon Stock ExchangeEuronext DublinOther stakeholders Date        15.01.2024 Share buy-back programme – week 2 The share buy-back programme runs from and including 3 August 2023 up to and including 22 January 2024. During this period Ringkjøbing Landbobank will buy-back shares to a maximum market value of DKK 385 million under a share buy-back programme, see company announcement of 2 August 2023. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme:Date Number of shares Average purchase price (DKK) Total purchased under the programme (DKK)Total in accordance with the last...

Investor News 15 January 2024 NKT has placed order for new cable-laying vessel In May 2023, on the back of a record order backlog and the strong market outlook, NKT announced investments in a new high-voltage factory on the existing site in Karlskrona and a new market leading cable-laying vessel. The order for the construction of the vessel has now been placed with Norwegian shipyard Vard. The vessel will be designed by the Norwegian company Salt Ship Design AS. The vessel will be constructed in parallel with NKT expanding its site in Karlskrona, Sweden, and both assets are expected operational from 2027. ContactInvestor Relations:         Michael Nass Nielsen, Head of Investor Relations, Tel.: +45 2494 1654Press:                           Louise W. Naldal, Head of Group Communications, Tel: +45 2982 0022AttachmentNKT...

Company announcement no. 3 / 2024Schindellegi, Switzerland – 15 January 2024 Trifork Holding AG – Weekly report on share buyback On 2 November 2023, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 November 2023 up to and including no later than 31 March 2024. For details, please see announcement no. 17 of 31 October 2023. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 15 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 232,497 treasury shares, corresponding to 1.2% of the share capital. Under the program, the following transactions have been...

Uponor Corporation, Stock Exchange Release, 15 January 2024 at 08:55 EET Uponor Corporation: Cancellation of treasury shares registered The Board of Directors of Uponor Corporation has decided to cancel a total of 373,685 treasury shares. The cancellation of the treasury shares has been registered with the Trade Register maintained by the Finnish Patent and Registration Office today, 15 January 2024. Prior to the cancellation of the treasury shares, the total number of shares in Uponor Corporation was 73,206,944. After the cancellation, the total number of shares in Uponor Corporation is 72,833,259 and the total number of votes attached to the shares is 72,833,259. After the cancellation, Uponor Corporation does not hold any shares in the Company. The cancellation of treasury sales has no effect on the share capital of Uponor Corporation. Further...

VANCOUVER, Canada, Jan. 15, 2024 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is proud to introduce Sirona LaboratoriesTM – a wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMimTM. Dr. Howard Verrico, CEO and founder of Sirona Biochem, expressed his enthusiasm for the major milestone, stating that the establishment of Sirona Laboratories is meant to not just shape the future of the company, but to revolutionize the global anti-aging skincare market. The announcement follows the recent decision to trademark GlycoProteMim. The extraordinary results from the active ingredient’s clinical trials prompted the company’s strategic decision to establish Sirona Laboratories, which will redefine its trajectory in the...

Multitude’s 3rd Annual “Charity of Your Choice” Initiative Achieves Milestone, Contributing a total of EUR 71,350 to Inspire Giving and Impactful Change Helsinki, 15 January 2024 – Multitude SE – a fully regulated international growth platform for financial technology (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude” or “the Group”) proudly announces the successful conclusion of its 3rd annual “Charity of Your Choice” initiative, following a robust voting process, where employees from over 25 global locations nominated 50 charitable organisations, resulting in a donation of over EUR 17,000 in 2023. The initiative’s unique aspect is the engaging pitch sessions, where employees advocate for their chosen charities by casting a live-vote during one of the company’s All Staff gatherings,...

Oslo, 15 January 2024 – DNO ASA, the Norwegian oil and gas operator, will publish its Q4 2023 operating and interim financial results on 8 February at 07:00 (CET). A videoconference call with executive management will follow at 14:00 (CET). The Company issues below an update on production and sales volumes for the quarter as well as other key financial information that will be further discussed in the earnings call.Volumes (boepd)Gross operated production Q4 2023 Q3 2023 Q4 2022Kurdistan 65,773 25,984 107,822North Sea – – –       Net entitlement production Q4 2023 Q3 2023 Q4 2022Kurdistan 26,057 9,897 25,618North Sea 16,879 14,288 14,976       Sales Q4 2023 Q3 2023 Q4 2022Kurdistan 26,057 9,897 25,618North Sea 15,628 15,749 15,152       Equity accounted production (net) Q4 2023 Q3...

AGAMREE® is the only approved medication in the European Union (EU) for treating all patients from age 4 years with DMD, and the first DMD treatment approved across the U.S., EU and UK This marks the first commercial launch of AGAMREE® globallyPratteln, Switzerland, January 15, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older, irrespective of the underlying mutation and ambulatory status, in Germany. AGAMREE® is the first and only medicinal product for DMD to have received full approval in the EU and, following approval in the U.S. last October and in the UK last week, it is the first authorized treatment for patients with the disease in all three territories. “We are very happy that AGAMREE is now commercially...